1. Home
  2. USA vs ORKA Comparison

USA vs ORKA Comparison

Compare USA & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

USA

Liberty All-Star Equity Fund

HOLD

Current Price

$5.78

Market Cap

1.9B

Sector

Finance

ML Signal

HOLD

Logo Oruka Therapeutics Inc.

ORKA

Oruka Therapeutics Inc.

HOLD

Current Price

$68.36

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
USA
ORKA
Founded
N/A
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.6B
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
USA
ORKA
Price
$5.78
$68.36
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
$73.33
AVG Volume (30 Days)
1.2M
1.2M
Earning Date
01-01-0001
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.40
$8.91
52 Week High
$6.96
$71.00

Technical Indicators

Market Signals
Indicator
USA
ORKA
Relative Strength Index (RSI) 51.72 73.48
Support Level $5.40 $26.02
Resistance Level $6.05 N/A
Average True Range (ATR) 0.07 3.57
MACD 0.01 -0.05
Stochastic Oscillator 51.10 86.13

Price Performance

Historical Comparison
USA
ORKA

About USA Liberty All-Star Equity Fund

Liberty All Star Equity Fund is a multi-managed fund. Its objective is to provide a high level of current income and long-term capital appreciation through investing principally in a diversified portfolio of equity securities. The fund invests in various sectors, including financials, information technology, healthcare, consumer discretionary, consumer staples, industrials, energy, materials, real estate, utilities, telecommunication, and other services.

About ORKA Oruka Therapeutics Inc.

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Share on Social Networks: